nodes	percent_of_prediction	percent_of_DWPC	metapath
Aripiprazole—H1F0—ocular cancer	0.953	1	CbGaD
Aripiprazole—Ziprasidone—H1F0—ocular cancer	0.0043	1	CrCbGaD
Aripiprazole—CYP3A4—Metabolism—GNA11—ocular cancer	5.32e-06	0.000126	CbGpPWpGaD
Aripiprazole—DRD5—Signaling Pathways—HRAS—ocular cancer	5.32e-06	0.000126	CbGpPWpGaD
Aripiprazole—HTR1E—Signaling Pathways—AKT1—ocular cancer	5.31e-06	0.000126	CbGpPWpGaD
Aripiprazole—CYP3A7—Metabolism—EP300—ocular cancer	5.29e-06	0.000125	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—CDKN1B—ocular cancer	5.29e-06	0.000125	CbGpPWpGaD
Aripiprazole—DRD1—Signaling by GPCR—AKT1—ocular cancer	5.28e-06	0.000125	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—MDM2—ocular cancer	5.27e-06	0.000125	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—CDKN1B—ocular cancer	5.24e-06	0.000124	CbGpPWpGaD
Aripiprazole—ADRB1—GPCR downstream signaling—AKT1—ocular cancer	5.23e-06	0.000124	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—MYC—ocular cancer	5.23e-06	0.000124	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—MYC—ocular cancer	5.22e-06	0.000123	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—TGFB1—ocular cancer	5.21e-06	0.000123	CbGpPWpGaD
Aripiprazole—DRD3—Signaling by GPCR—AKT1—ocular cancer	5.21e-06	0.000123	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—TGFB1—ocular cancer	5.21e-06	0.000123	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—MYC—ocular cancer	5.19e-06	0.000123	CbGpPWpGaD
Aripiprazole—ADRA2B—GPCR downstream signaling—AKT1—ocular cancer	5.18e-06	0.000123	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—TGFB1—ocular cancer	5.17e-06	0.000122	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—EP300—ocular cancer	5.16e-06	0.000122	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling by GPCR—HRAS—ocular cancer	5.14e-06	0.000122	CbGpPWpGaD
Aripiprazole—ADRA2C—Metabolism—EP300—ocular cancer	5.14e-06	0.000122	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling by GPCR—HRAS—ocular cancer	5.12e-06	0.000121	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—EP300—ocular cancer	5.09e-06	0.00012	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—MYC—ocular cancer	5.08e-06	0.00012	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—TGFB1—ocular cancer	5.07e-06	0.00012	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—CDKN1B—ocular cancer	5.06e-06	0.00012	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—CCND1—ocular cancer	5.04e-06	0.000119	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—CDKN1B—ocular cancer	5.03e-06	0.000119	CbGpPWpGaD
Aripiprazole—HTR1A—GPCR downstream signaling—AKT1—ocular cancer	5e-06	0.000118	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—MYC—ocular cancer	5e-06	0.000118	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—CCND1—ocular cancer	5e-06	0.000118	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—TGFB1—ocular cancer	4.98e-06	0.000118	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling by GPCR—HRAS—ocular cancer	4.98e-06	0.000118	CbGpPWpGaD
Aripiprazole—HTR2C—GPCR downstream signaling—AKT1—ocular cancer	4.97e-06	0.000118	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—GNAQ—ocular cancer	4.95e-06	0.000117	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—MYC—ocular cancer	4.93e-06	0.000117	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—TGFB1—ocular cancer	4.92e-06	0.000116	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling by GPCR—HRAS—ocular cancer	4.9e-06	0.000116	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—CDKN1B—ocular cancer	4.89e-06	0.000116	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—CDKN1A—ocular cancer	4.88e-06	0.000115	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—MDM2—ocular cancer	4.86e-06	0.000115	CbGpPWpGaD
Aripiprazole—ADRA2C—GPCR downstream signaling—AKT1—ocular cancer	4.84e-06	0.000114	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—CDKN1A—ocular cancer	4.83e-06	0.000114	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—CCND1—ocular cancer	4.82e-06	0.000114	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—CDKN1B—ocular cancer	4.81e-06	0.000114	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—CCND1—ocular cancer	4.8e-06	0.000114	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—MDM2—ocular cancer	4.78e-06	0.000113	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—MDM2—ocular cancer	4.77e-06	0.000113	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—MYC—ocular cancer	4.77e-06	0.000113	CbGpPWpGaD
Aripiprazole—ADRA1B—GPCR downstream signaling—AKT1—ocular cancer	4.76e-06	0.000113	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—TGFB1—ocular cancer	4.76e-06	0.000113	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—MDM2—ocular cancer	4.76e-06	0.000113	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling by GPCR—AKT1—ocular cancer	4.75e-06	0.000112	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—MDM2—ocular cancer	4.74e-06	0.000112	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—MYC—ocular cancer	4.72e-06	0.000112	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—TGFB1—ocular cancer	4.71e-06	0.000111	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling by GPCR—AKT1—ocular cancer	4.7e-06	0.000111	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—MDM2—ocular cancer	4.7e-06	0.000111	CbGpPWpGaD
Aripiprazole—DRD5—Signaling Pathways—AKT1—ocular cancer	4.7e-06	0.000111	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—MDM2—ocular cancer	4.68e-06	0.000111	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—CCND1—ocular cancer	4.67e-06	0.00011	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—CDKN1A—ocular cancer	4.67e-06	0.00011	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—CDKN1A—ocular cancer	4.64e-06	0.00011	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—EP300—ocular cancer	4.64e-06	0.00011	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—EP300—ocular cancer	4.6e-06	0.000109	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—CCND1—ocular cancer	4.59e-06	0.000109	CbGpPWpGaD
Aripiprazole—CHRM3—Metabolism—EP300—ocular cancer	4.55e-06	0.000108	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling by GPCR—AKT1—ocular cancer	4.54e-06	0.000107	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling by GPCR—AKT1—ocular cancer	4.52e-06	0.000107	CbGpPWpGaD
Aripiprazole—DRD2—Signaling by GPCR—HRAS—ocular cancer	4.52e-06	0.000107	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—CDKN1A—ocular cancer	4.51e-06	0.000107	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—MYC—ocular cancer	4.5e-06	0.000106	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—TGFB1—ocular cancer	4.49e-06	0.000106	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling by GPCR—HRAS—ocular cancer	4.44e-06	0.000105	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—CDKN1A—ocular cancer	4.44e-06	0.000105	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—EP300—ocular cancer	4.44e-06	0.000105	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—CDKN1B—ocular cancer	4.44e-06	0.000105	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—MYC—ocular cancer	4.44e-06	0.000105	CbGpPWpGaD
Aripiprazole—HRH1—Signaling by GPCR—HRAS—ocular cancer	4.43e-06	0.000105	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—TGFB1—ocular cancer	4.43e-06	0.000105	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling by GPCR—HRAS—ocular cancer	4.42e-06	0.000105	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—EP300—ocular cancer	4.42e-06	0.000104	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling by GPCR—HRAS—ocular cancer	4.41e-06	0.000104	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling by GPCR—AKT1—ocular cancer	4.39e-06	0.000104	CbGpPWpGaD
Aripiprazole—DRD2—GPCR downstream signaling—AKT1—ocular cancer	4.39e-06	0.000104	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—CDKN1B—ocular cancer	4.37e-06	0.000103	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling by GPCR—HRAS—ocular cancer	4.36e-06	0.000103	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—CDKN1B—ocular cancer	4.36e-06	0.000103	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—MDM2—ocular cancer	4.35e-06	0.000103	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling by GPCR—HRAS—ocular cancer	4.35e-06	0.000103	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—CDKN1B—ocular cancer	4.34e-06	0.000103	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—CDKN1B—ocular cancer	4.33e-06	0.000102	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling by GPCR—AKT1—ocular cancer	4.32e-06	0.000102	CbGpPWpGaD
Aripiprazole—HTR2A—GPCR downstream signaling—AKT1—ocular cancer	4.32e-06	0.000102	CbGpPWpGaD
Aripiprazole—HRH1—GPCR downstream signaling—AKT1—ocular cancer	4.31e-06	0.000102	CbGpPWpGaD
Aripiprazole—CHRM1—GPCR downstream signaling—AKT1—ocular cancer	4.3e-06	0.000102	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—EP300—ocular cancer	4.3e-06	0.000102	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—TP53—ocular cancer	4.29e-06	0.000102	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—CDKN1B—ocular cancer	4.29e-06	0.000101	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—TP53—ocular cancer	4.29e-06	0.000101	CbGpPWpGaD
Aripiprazole—CHRM3—GPCR downstream signaling—AKT1—ocular cancer	4.28e-06	0.000101	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—CDKN1B—ocular cancer	4.28e-06	0.000101	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—TP53—ocular cancer	4.26e-06	0.000101	CbGpPWpGaD
Aripiprazole—CHRM2—GPCR downstream signaling—AKT1—ocular cancer	4.24e-06	0.0001	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—CCND1—ocular cancer	4.23e-06	0.0001	CbGpPWpGaD
Aripiprazole—ADRA1A—GPCR downstream signaling—AKT1—ocular cancer	4.23e-06	0.0001	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—EP300—ocular cancer	4.23e-06	0.0001	CbGpPWpGaD
Aripiprazole—ADRA2A—Metabolism—EP300—ocular cancer	4.17e-06	9.87e-05	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—TP53—ocular cancer	4.17e-06	9.87e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—CCND1—ocular cancer	4.17e-06	9.86e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—CCND1—ocular cancer	4.16e-06	9.84e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—CCND1—ocular cancer	4.14e-06	9.8e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—CCND1—ocular cancer	4.13e-06	9.77e-05	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—HRAS—ocular cancer	4.1e-06	9.71e-05	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—TP53—ocular cancer	4.1e-06	9.71e-05	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—HRAS—ocular cancer	4.1e-06	9.7e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—CDKN1A—ocular cancer	4.1e-06	9.69e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—CCND1—ocular cancer	4.09e-06	9.68e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—CCND1—ocular cancer	4.08e-06	9.65e-05	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—HRAS—ocular cancer	4.07e-06	9.64e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—TP53—ocular cancer	4.05e-06	9.58e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—MYC—ocular cancer	4.04e-06	9.57e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling by GPCR—HRAS—ocular cancer	4.04e-06	9.56e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—TGFB1—ocular cancer	4.03e-06	9.54e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—CDKN1A—ocular cancer	4.03e-06	9.53e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—CDKN1A—ocular cancer	4.02e-06	9.51e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—CDKN1A—ocular cancer	4.01e-06	9.48e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—MYC—ocular cancer	4.01e-06	9.48e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—TGFB1—ocular cancer	4e-06	9.46e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—CDKN1A—ocular cancer	4e-06	9.45e-05	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—HRAS—ocular cancer	3.99e-06	9.44e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling by GPCR—AKT1—ocular cancer	3.99e-06	9.43e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—CDKN1B—ocular cancer	3.97e-06	9.4e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—CDKN1A—ocular cancer	3.96e-06	9.36e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—CDKN1A—ocular cancer	3.95e-06	9.34e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—GPCR downstream signaling—AKT1—ocular cancer	3.93e-06	9.3e-05	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—HRAS—ocular cancer	3.92e-06	9.28e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling by GPCR—AKT1—ocular cancer	3.92e-06	9.28e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—TP53—ocular cancer	3.92e-06	9.27e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling by GPCR—AKT1—ocular cancer	3.91e-06	9.26e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling by GPCR—AKT1—ocular cancer	3.9e-06	9.23e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—EP300—ocular cancer	3.9e-06	9.22e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling by GPCR—AKT1—ocular cancer	3.89e-06	9.2e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—TP53—ocular cancer	3.88e-06	9.17e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—HRAS—ocular cancer	3.87e-06	9.16e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—MYC—ocular cancer	3.87e-06	9.15e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—TGFB1—ocular cancer	3.86e-06	9.13e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling by GPCR—AKT1—ocular cancer	3.85e-06	9.11e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—MYC—ocular cancer	3.85e-06	9.1e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling by GPCR—AKT1—ocular cancer	3.84e-06	9.09e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—TGFB1—ocular cancer	3.84e-06	9.08e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—EP300—ocular cancer	3.84e-06	9.07e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—EP300—ocular cancer	3.83e-06	9.05e-05	CbGpPWpGaD
Aripiprazole—CYP3A5—Metabolism—EP300—ocular cancer	3.82e-06	9.05e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—EP300—ocular cancer	3.81e-06	9.02e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—EP300—ocular cancer	3.8e-06	9e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—CCND1—ocular cancer	3.79e-06	8.97e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—EP300—ocular cancer	3.77e-06	8.91e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—EP300—ocular cancer	3.76e-06	8.88e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—HRAS—ocular cancer	3.75e-06	8.86e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—MYC—ocular cancer	3.74e-06	8.86e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—TGFB1—ocular cancer	3.73e-06	8.83e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—HRAS—ocular cancer	3.71e-06	8.77e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—TP53—ocular cancer	3.69e-06	8.74e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—MYC—ocular cancer	3.68e-06	8.72e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—TGFB1—ocular cancer	3.67e-06	8.69e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—CDKN1A—ocular cancer	3.67e-06	8.67e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—TP53—ocular cancer	3.65e-06	8.62e-05	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—AKT1—ocular cancer	3.62e-06	8.57e-05	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—AKT1—ocular cancer	3.62e-06	8.56e-05	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—AKT1—ocular cancer	3.6e-06	8.51e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling by GPCR—AKT1—ocular cancer	3.57e-06	8.44e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—HRAS—ocular cancer	3.53e-06	8.36e-05	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—AKT1—ocular cancer	3.52e-06	8.33e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—EP300—ocular cancer	3.49e-06	8.25e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—HRAS—ocular cancer	3.49e-06	8.25e-05	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—AKT1—ocular cancer	3.47e-06	8.2e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—AKT1—ocular cancer	3.42e-06	8.09e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—MYC—ocular cancer	3.4e-06	8.03e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—TGFB1—ocular cancer	3.39e-06	8.02e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—MYC—ocular cancer	3.34e-06	7.91e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—MYC—ocular cancer	3.33e-06	7.89e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—TGFB1—ocular cancer	3.33e-06	7.89e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—TGFB1—ocular cancer	3.33e-06	7.87e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—MYC—ocular cancer	3.32e-06	7.86e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—TP53—ocular cancer	3.32e-06	7.86e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—TGFB1—ocular cancer	3.32e-06	7.84e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—MYC—ocular cancer	3.31e-06	7.84e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—AKT1—ocular cancer	3.31e-06	7.83e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—TGFB1—ocular cancer	3.31e-06	7.82e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—TP53—ocular cancer	3.29e-06	7.79e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—MYC—ocular cancer	3.28e-06	7.76e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—AKT1—ocular cancer	3.27e-06	7.74e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—TGFB1—ocular cancer	3.27e-06	7.74e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—MYC—ocular cancer	3.27e-06	7.74e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—TGFB1—ocular cancer	3.26e-06	7.72e-05	CbGpPWpGaD
Aripiprazole—CYP3A7—Metabolism—AKT1—ocular cancer	3.2e-06	7.56e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—TP53—ocular cancer	3.18e-06	7.52e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—HRAS—ocular cancer	3.18e-06	7.51e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—TP53—ocular cancer	3.16e-06	7.48e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—HRAS—ocular cancer	3.15e-06	7.45e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—AKT1—ocular cancer	3.12e-06	7.38e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Metabolism—AKT1—ocular cancer	3.1e-06	7.34e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—AKT1—ocular cancer	3.08e-06	7.28e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—TP53—ocular cancer	3.07e-06	7.27e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—MYC—ocular cancer	3.04e-06	7.19e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—HRAS—ocular cancer	3.04e-06	7.19e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—TGFB1—ocular cancer	3.03e-06	7.18e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—TP53—ocular cancer	3.03e-06	7.16e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—HRAS—ocular cancer	3.02e-06	7.15e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—HRAS—ocular cancer	2.94e-06	6.95e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—HRAS—ocular cancer	2.89e-06	6.84e-05	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—EP300—ocular cancer	2.89e-06	6.83e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—AKT1—ocular cancer	2.8e-06	6.63e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—TP53—ocular cancer	2.79e-06	6.6e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—AKT1—ocular cancer	2.78e-06	6.57e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Metabolism—AKT1—ocular cancer	2.75e-06	6.5e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—TP53—ocular cancer	2.74e-06	6.49e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—TP53—ocular cancer	2.74e-06	6.48e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—TP53—ocular cancer	2.73e-06	6.46e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—TP53—ocular cancer	2.72e-06	6.44e-05	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—EP300—ocular cancer	2.72e-06	6.43e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—TP53—ocular cancer	2.69e-06	6.37e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—TP53—ocular cancer	2.69e-06	6.36e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—AKT1—ocular cancer	2.68e-06	6.35e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—AKT1—ocular cancer	2.67e-06	6.31e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—HRAS—ocular cancer	2.67e-06	6.31e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—HRAS—ocular cancer	2.62e-06	6.21e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—HRAS—ocular cancer	2.62e-06	6.2e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—HRAS—ocular cancer	2.61e-06	6.18e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—HRAS—ocular cancer	2.6e-06	6.16e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—AKT1—ocular cancer	2.6e-06	6.14e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—HRAS—ocular cancer	2.58e-06	6.1e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—HRAS—ocular cancer	2.57e-06	6.08e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—AKT1—ocular cancer	2.55e-06	6.04e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Metabolism—AKT1—ocular cancer	2.52e-06	5.97e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—TP53—ocular cancer	2.5e-06	5.91e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—HRAS—ocular cancer	2.39e-06	5.65e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—AKT1—ocular cancer	2.36e-06	5.57e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—AKT1—ocular cancer	2.32e-06	5.48e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—AKT1—ocular cancer	2.31e-06	5.47e-05	CbGpPWpGaD
Aripiprazole—CYP3A5—Metabolism—AKT1—ocular cancer	2.31e-06	5.47e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—AKT1—ocular cancer	2.31e-06	5.45e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—AKT1—ocular cancer	2.3e-06	5.44e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—AKT1—ocular cancer	2.28e-06	5.38e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—AKT1—ocular cancer	2.27e-06	5.37e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—AKT1—ocular cancer	2.11e-06	4.99e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—EP300—ocular cancer	1.78e-06	4.21e-05	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—AKT1—ocular cancer	1.74e-06	4.12e-05	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—AKT1—ocular cancer	1.64e-06	3.89e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—AKT1—ocular cancer	1.07e-06	2.54e-05	CbGpPWpGaD
